Hepatic Tumor Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therape

Hepatic Tumor Pipeline constitutes 75+ key companies continuously working towards developing 75+ Hepatic Tumor treatment therapies, analyzes DelveInsight.

Hepatic Tumor Overview:

Hepatic tumors, or liver tumors, refer to a range of growths that can form in the liver, either benign or malignant. The most common types include hepatocellular carcinoma (HCC), which develops from liver cells (hepatocytes), and cholangiocarcinoma, which originates from bile ducts. Other types include hepatic adenomas, focal nodular hyperplasia, and hemangiomas.

The causes of hepatic tumors are diverse and can include chronic liver conditions like hepatitis B or C, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), and certain genetic disorders. Environmental factors such as exposure to aflatoxins, found in moldy grains and nuts, and lifestyle factors like obesity, smoking, and heavy alcohol consumption also increase the risk.

Symptoms can vary depending on the tumor type and size, with common signs including abdominal pain, weight loss, loss of appetite, nausea, jaundice, and liver enlargement. Diagnosis typically involves imaging tests (ultrasound, CT, or MRI) and blood tests for liver function and tumor markers. Treatment options depend on the tumor type and stage, and may include surgery, chemotherapy, radiation, targeted therapy, or liver transplant. Early detection is key to improving outcomes.

Request for a detailed insights report on Hepatic Tumor pipeline insights @ https://www.delveinsight.com/report-store/hepatic-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Hepatic Tumor Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hepatic Tumor Therapeutics Market.

Key Takeaways from the Hepatic Tumor Pipeline Report

DelveInsight's Hepatic Tumor pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Hepatic Tumor treatment.
In December 2024, Galectin Therapeutics reported results from its global NAVIGATE clinical trial, which assessed belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.
In October 2024, PharmaIN Corporation revealed that it would present interim findings from its ongoing Phase I clinical trial of PHIN-214, its lead candidate, for preventing and treating decompensated cirrhosis.
In June 2024, Carisma Therapeutics Inc. announced the selection of its first development candidate from its collaboration with Moderna, Inc. The candidate is an in vivo CAR-M targeting Glypican-3, designed to treat solid tumors such as hepatocellular carcinoma. This milestone triggered a $2 million payment to Carisma.
In June 2024, Resolution Therapeutics Limited shared important data on RTX001 in collaboration with the University of Edinburgh at the EASL Congress 2024 in Milan, Italy, highlighting the potential of macrophage cell therapy for treating advanced liver cirrhosis.
In June 2024, Lipocine presented Phase II results for LPCN 1148 in cirrhosis at the European Association for the Study of Liver (EASL) Congress in Milan, Italy, through a late-breaking oral presentation.
In May 2024, Ascelia Pharma AB reported that its liver imaging drug candidate, Orviglance, significantly improved the visualization of focal liver lesions, successfully meeting the primary endpoint in the pivotal Phase III SPARKLE study.
In April 2024, LyGenesis announced the first patient had been treated in its Phase IIa clinical trial of its first-in-class allogenic regenerative cell therapy, which is transplanted into patients' lymph nodes as a potential treatment for end-stage liver disease (ESLD).
In March 2024, Lipocine announced positive topline results from its Phase II study of LPCN 1148, an oral candidate being developed for the clinical management of liver cirrhosis.
In February 2024, Immune-Onc Therapeutics, Inc. revealed a Phase Ib/II clinical trial collaboration with Roche to evaluate Immune-Onc's IO-108, a first-in-class antibody targeting LILRB2 (ILT4), in combination with Roche's atezolizumab and bevacizumab for treating patients with locally advanced, metastatic, and/or unresectable hepatocellular carcinoma (HCC).
In February 2024, Biosyngen announced that BST02 received Fast Track Designation from the U.S. FDA for the treatment of all liver cancer types, including hepatocellular carcinoma and cholangiocarcinoma.
In January 2024, CARsgen Therapeutics Holdings Limited announced that CT011 received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) for patients with GPC3-positive stage IIIa hepatocellular carcinoma at high risk of recurrence after surgical resection.
Key Hepatic Tumor companies such as Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab, Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., Eureka Therapeutics Inc., and others are evaluating new drugs for Hepatic Tumor to improve the treatment landscape.
Promising Hepatic Tumor pipeline therapies in various stages of development include Namodenoson, MTL CEBPA, Amivantamab, Fostroxacitabine bralpamide, ETN101, and others.

Hepatic Tumor Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Hepatic Tumor Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatic Tumor treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hepatic Tumor market.

Download our free sample page report on Hepatic Tumor pipeline insights @ https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hepatic Tumor Emerging Drugs

Namodenoson: Can Fite Biopharma
MTL CEBPA : MiNA Therapeutics
Amivantamab: Janssen Research & Development, LLC
Fostroxacitabine bralpamide: Medivir AB
ETN101: Etnova Therapeutics Corp.

Hepatic Tumor Companies

More than 75 major companies are working on developing therapies for hepatic tumors. Among them, Can Fite Biopharma has drug candidates for hepatic tumors in the most advanced stage, Phase III.

DelveInsight's report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Hepatic Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Hepatic Tumor Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Hepatic Tumor Therapies and Key Companies: Hepatic Tumor Clinical Trials and advancements @ https://www.delveinsight.com/report-store/hepatic-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hepatic Tumor Pipeline Therapeutic Assessment
• Hepatic Tumor Assessment by Product Type
• Hepatic Tumor By Stage
• Hepatic Tumor Assessment by Route of Administration
• Hepatic Tumor Assessment by Molecule Type

Download Hepatic Tumor Sample report to know in detail about the Hepatic Tumor treatment market @ Hepatic Tumor Therapeutic Assessment @ https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Hepatic Tumor Current Treatment Patterns
4. Hepatic Tumor - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hepatic Tumor Late-Stage Products (Phase-III)
7. Hepatic Tumor Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hepatic Tumor Discontinued Products
13. Hepatic Tumor Product Profiles
14. Hepatic Tumor Key Companies
15. Hepatic Tumor Key Products
16. Dormant and Discontinued Products
17. Hepatic Tumor Unmet Needs
18. Hepatic Tumor Future Perspectives
19. Hepatic Tumor Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Hepatic Tumor Pipeline Reports Offerings: https://www.delveinsight.com/report-store/hepatic-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.